CSL BEHRING LLC — Lobbying Disclosure | Poliscope

CSL BEHRING LLC

View full entity profile (contributions, contracts, SEC) →

This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.

Lobbying Spend

$17.2M

Filings

139

Firms Hired

Active Period

2006–2026

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2026	$1,260,000	9	3
2025	$2,220,000	16	4
2024	$1,320,000	15	4
2023	$980,000	9	2
2022	$1,700,000	9	2
2021	$1,200,000	8	2
2020	$1,050,000	11	2
2019	$910,000	9	2
2018	$780,000	4	1
2017	$400,000	4	1
2016	$600,000	4	1
2015	$700,000	4	1
2014	$1,020,000	6	1
2013	$590,000	4	1
2012	$530,000	4	1
2011	$490,000	4	1
2010	$270,000	4	1
2009	$300,000	5	1
2008	$300,000	4	1
2007	$260,000	2	1
2006	$360,000	4	1

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
CSL BEHRING LLC	$17,240,000	86
THE NICKLES GROUP, LLC	—	35
SPLITOAK STRATEGIES LLC	—	11
HARBINGER STRATEGIES, LLC	—	7

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	130
SENATE	129
Centers For Medicare and Medicaid Services (CMS)	41
Health & Human Services, Dept of (HHS)	38
Treasury, Dept of	16
Executive Office of the President (EOP)	7
Food & Drug Administration (FDA)	6
Office of Management & Budget (OMB)	6
White House Office	6
Homeland Security, Dept of (DHS)	3
Internal Revenue Service (IRS)	3
U.S. Customs & Border Protection	1
UNDETERMINED	1

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Health Issues	Health Issues	104
Medicare/Medicaid	Medicare/Medicaid	73
Taxation/Internal Revenue Code	Taxation/Internal Revenue Code	66
Trade (domestic/foreign)	Trade (domestic/foreign)	15
Homeland Security	Homeland Security	12
Government Issues	Government Issues	11
Immigration	Immigration	9
Budget/Appropriations	Budget/Appropriations	7
Medical/Disease Research/Clinical Labs	Medical/Disease Research/Clinical Labs	1
Banking	Banking	1

Bills Explicitly Cited (25)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 1476119th Congress

PLASMA Act

2026 · third_quarter · Firm: CSL BEHRING LLC

Open original LDA filing ↗

Cited source text and reported amounts

Medicare Part D phase-in of manufacturer liability H.R 1476 PLASMA Act

Client expense: $420,000 · Firm income: —

Matched citations: H.R 1476

H.R. 1476119th Congress

PLASMA Act

2026 · third_quarter · Firm: SPLITOAK STRATEGIES LLC

Open original LDA filing ↗

Cited source text and reported amounts

H.R.1476/S.694, PLASMA Act

Client expense: — · Firm income: $40,000

Matched citations: H.R.1476

S. 694119th Congress

PLASMA Act

2026 · third_quarter · Firm: SPLITOAK STRATEGIES LLC

Open original LDA filing ↗

Cited source text and reported amounts

H.R.1476/S.694, PLASMA Act

Client expense: — · Firm income: $40,000

Matched citations: S.694

H.R. 1119th Congress

An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.

2026 · third_quarter · Firm: THE NICKLES GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Monitored implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to foreign-based corporations, and corporate taxes. Issues related to the OECD Pillar II exemption for the U.S.

Client expense: — · Firm income: $50,000

Matched citations: H.R. 1

Show 21 more cited filings

H.R. 1476119th Congress

PLASMA Act

2026 · third_quarter · Firm: THE NICKLES GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to plasma based therapies. H.R. 1476 / S. 694, Preserving Life-saving Access to Specialty Medicines in America (PLASMA) Act. Issues related to gene therapies. Issues related to drug shortages. Monitored implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to plasma derived products and drug pricing. Issues related to pharmacy benefit management reforms. Issues regarding plasma-based therapies. Issues related to Most Favored Nation drug pricing.

Client expense: — · Firm income: $50,000

Matched citations: H.R. 1476

S. 694119th Congress

PLASMA Act

2026 · third_quarter · Firm: THE NICKLES GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to plasma based therapies. H.R. 1476 / S. 694, Preserving Life-saving Access to Specialty Medicines in America (PLASMA) Act. Issues related to gene therapies. Issues related to drug shortages. Monitored implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to plasma derived products and drug pricing. Issues related to pharmacy benefit management reforms. Issues regarding plasma-based therapies. Issues related to Most Favored Nation drug pricing.

Client expense: — · Firm income: $50,000

Matched citations: S. 694

H.R. 1476119th Congress

PLASMA Act

2026 · second_quarter · Firm: SPLITOAK STRATEGIES LLC

Open original LDA filing ↗

Cited source text and reported amounts

H.R.1476/S.694, PLASMA Act

Client expense: — · Firm income: $40,000

Matched citations: H.R.1476

S. 694119th Congress

PLASMA Act

2026 · second_quarter · Firm: SPLITOAK STRATEGIES LLC

Open original LDA filing ↗

Cited source text and reported amounts

H.R.1476/S.694, PLASMA Act

Client expense: — · Firm income: $40,000

Matched citations: S.694

H.R. 1476119th Congress

PLASMA Act

2026 · second_quarter · Firm: CSL BEHRING LLC

Open original LDA filing ↗

Cited source text and reported amounts

Medicare Part D phase-in of manufacturer liability; Issues related to Medicare Most Favored Nation H.R 1476 PLASMA Act

Client expense: $380,000 · Firm income: —

Matched citations: H.R 1476

H.R. 1119th Congress

An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.

2026 · second_quarter · Firm: THE NICKLES GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Monitored implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to foreign-based corporations, and corporate taxes. Issues related to the OECD Pillar II exemption for the U.S.

Client expense: — · Firm income: $50,000

Matched citations: H.R. 1

H.R. 1476119th Congress

PLASMA Act

2026 · second_quarter · Firm: THE NICKLES GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to plasma based therapies. H.R. 1476 / S. 694, Preserving Life-saving Access to Specialty Medicines in America (PLASMA) Act. Issues related to gene therapies. Issues related to value-based payments. Issues related to drug shortages. Monitored implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to plasma derived products and drug pricing. Issues related to pharmacy benefit management. Issues related to Most Favored Nation drug pricing.

Client expense: — · Firm income: $50,000

Matched citations: H.R. 1476

S. 694119th Congress

PLASMA Act

2026 · second_quarter · Firm: THE NICKLES GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to plasma based therapies. H.R. 1476 / S. 694, Preserving Life-saving Access to Specialty Medicines in America (PLASMA) Act. Issues related to gene therapies. Issues related to value-based payments. Issues related to drug shortages. Monitored implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to plasma derived products and drug pricing. Issues related to pharmacy benefit management. Issues related to Most Favored Nation drug pricing.

Client expense: — · Firm income: $50,000

Matched citations: S. 694

H.R. 1476119th Congress

PLASMA Act

2026 · first_quarter · Firm: SPLITOAK STRATEGIES LLC

Open original LDA filing ↗

Cited source text and reported amounts

H.R.1476/S.694, PLASMA Act

Client expense: — · Firm income: $40,000

Matched citations: H.R.1476

S. 694119th Congress

PLASMA Act

2026 · first_quarter · Firm: SPLITOAK STRATEGIES LLC

Open original LDA filing ↗

Cited source text and reported amounts

H.R.1476/S.694, PLASMA Act

Client expense: — · Firm income: $40,000

Matched citations: S.694

H.R. 1119th Congress

An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.

2026 · first_quarter · Firm: THE NICKLES GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Monitored implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to foreign-based corporations, and corporate taxes. Issues related to the OECD Pillar II exemption for the U.S.

Client expense: — · Firm income: $50,000

Matched citations: H.R. 1

H.R. 1476119th Congress

PLASMA Act

2026 · first_quarter · Firm: THE NICKLES GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to plasma based therapies. H.R. 1476 / S. 694, Preserving Life-saving Access to Specialty Medicines in America (PLASMA) Act. Issues related to gene therapies. Issues related to value-based payments. Issues related to drug shortages. Monitored implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to plasma derived products and drug pricing. Issues related to pharmacy benefit management. Issues related to Most Favored Nation drug pricing.

Client expense: — · Firm income: $50,000

Matched citations: H.R. 1476

S. 694119th Congress

PLASMA Act

2026 · first_quarter · Firm: THE NICKLES GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to plasma based therapies. H.R. 1476 / S. 694, Preserving Life-saving Access to Specialty Medicines in America (PLASMA) Act. Issues related to gene therapies. Issues related to value-based payments. Issues related to drug shortages. Monitored implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to plasma derived products and drug pricing. Issues related to pharmacy benefit management. Issues related to Most Favored Nation drug pricing.

Client expense: — · Firm income: $50,000

Matched citations: S. 694

H.R. 1476119th Congress

PLASMA Act

2025 · fourth_quarter · Firm: HARBINGER STRATEGIES, LLC

Open original LDA filing ↗

Cited source text and reported amounts

The PLASMA Act (H.R.1476/S.694): issues related to Part D and plasma-derived therapies.

Client expense: — · Firm income: $50,000

Matched citations: H.R.1476

S. 694119th Congress

PLASMA Act

2025 · fourth_quarter · Firm: HARBINGER STRATEGIES, LLC

Open original LDA filing ↗

Cited source text and reported amounts

The PLASMA Act (H.R.1476/S.694): issues related to Part D and plasma-derived therapies.

Client expense: — · Firm income: $50,000

Matched citations: S.694

H.R. 1476119th Congress

PLASMA Act

2025 · fourth_quarter · Firm: SPLITOAK STRATEGIES LLC

Open original LDA filing ↗

Cited source text and reported amounts

H.R.1476/S.694, PLASMA Act

Client expense: — · Firm income: $40,000

Matched citations: H.R.1476

S. 694119th Congress

PLASMA Act

2025 · fourth_quarter · Firm: SPLITOAK STRATEGIES LLC

Open original LDA filing ↗

Cited source text and reported amounts

H.R.1476/S.694, PLASMA Act

Client expense: — · Firm income: $40,000

Matched citations: S.694

H.R. 1119th Congress

An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.

2025 · fourth_quarter · Firm: THE NICKLES GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Monitored implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to foreign-based corporations, and corporate taxes. Issues related to the OECD Pillar II exemption for the U.S. H.R. 591, Defending American Jobs and Investment Act, and H.R. 2423, Unfair Tax Prevention Act, as they relate to multinational corporations.

Client expense: — · Firm income: $50,000

Matched citations: H.R. 1

H.R. 1476119th Congress

PLASMA Act

2025 · fourth_quarter · Firm: THE NICKLES GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to plasma based therapies. H.R. 1476 / S. 694, Preserving Life-saving Access to Specialty Medicines in America (PLASMA) Act. Issues related to gene therapies. Issues related to value-based payments. Issues related to drug shortages. Monitored implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to plasma derived products and drug pricing. Issues related to pharmacy benefit management. Issues related to Most Favored Nation drug pricing.

Client expense: — · Firm income: $50,000

Matched citations: H.R. 1476

H.R. 2423119th Congress

Unfair Tax Prevention Act

2025 · fourth_quarter · Firm: THE NICKLES GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Monitored implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to foreign-based corporations, and corporate taxes. Issues related to the OECD Pillar II exemption for the U.S. H.R. 591, Defending American Jobs and Investment Act, and H.R. 2423, Unfair Tax Prevention Act, as they relate to multinational corporations.

Client expense: — · Firm income: $50,000

Matched citations: H.R. 2423

H.R. 591119th Congress

Defending American Jobs and Investment Act

2025 · fourth_quarter · Firm: THE NICKLES GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Monitored implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to foreign-based corporations, and corporate taxes. Issues related to the OECD Pillar II exemption for the U.S. H.R. 591, Defending American Jobs and Investment Act, and H.R. 2423, Unfair Tax Prevention Act, as they relate to multinational corporations.

Client expense: — · Firm income: $50,000

Matched citations: H.R. 591

Source: Senate LDA